Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance
- 16 October 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 110 (4) , 420-425
Abstract
Men with early-stage prostate cancer have multiple options that have similar oncologic efficacy but vary in terms of their impact on quality of life. In low-risk cancer, active surveillance is the option that best preserves patients’ sexual function, but it is unknown if patient preference affects treatment selection. Our objectives were to identify patient characteristics associated with a strong preference to preserve sexual function and to determine whether patient preference and baseline sexual function level are associated with receipt of active surveillance in low-risk cancer. In this population-based cohort of men with localized prostate cancer, baseline patient-reported sexual function was assessed using a validated instrument. Patients were also asked whether preservation of sexual function was very, somewhat, or not important. Prostate cancer disease characteristics and treatments received were abstracted from medical records. A modified Poisson regression model with robust standard errors was used to compute adjusted risk ratio (aRR) estimates. All statistical tests were two-sided. Among 1194 men, 52.6% indicated a strong preference for preserving sexual function. Older men were less likely to have a strong preference (aRR = 0.98 per year, 95% confidence interval [CI] = 0.97 to 0.99), while men with normal sexual function were more likely (vs poor function, aRR = 1.59, 95% CI = 1.39 to 1.82). Among 568 men with low-risk cancer, there was no clear association between baseline sexual function or strong preference to preserve function with receipt of active surveillance. However, strong preference may differnetially impact those with intermediate baseline function vs poor function (Pinteraction = .02). Treatment choice may not always align with patients’ preferences. These findings demonstrate opportunities to improve delivery of patient-centered care in early prostate cancer.Keywords
Funding Information
- Patient-Centered Outcomes Research Institute (CER-1310-06453)
This publication has 35 references indexed in Scilit:
- Patient Preference and the Impact of Decision-Making Aids on Prostate Cancer Treatment Choices and Post-Intervention RegretCurrent Oncology, 2012
- Treatment decision‐making for localized prostate cancer: What younger men choose and whyThe Prostate, 2011
- Early prostate cancer – which treatment do men prefer and why?BJU International, 2010
- Patient Decision Aids for Prostate Cancer Treatment: A Systematic Review of the LiteratureCA: A Cancer Journal for Clinicians, 2009
- Predictors of patient preferences and treatment choices for localized prostate cancerCancer, 2008
- Doctors’ and Patients’ Preferences for Participation and Treatment in Curative Prostate Cancer RadiotherapyJournal of Clinical Oncology, 2007
- Bringing Prostate Cancer Quality of Life Research Back to the Bedside: Translating Numbers Into a Format That Patients can UnderstandJournal of Urology, 2006
- Patients' values and clinical substituted judgments: The case of localized prostate cancer.Health Psychology, 2005
- Measuring Patientsʼ Perceptions of the Outcomes of Treatment for Early Prostate CancerMedical Care, 2003
- Quality-of-life outcomes in men treated for localized prostate cancerJAMA, 1995